rivaroxaban + apixaban + warfarin

The combination of rivaroxaban, apixaban, and warfarin in this context refers to the anticoagulation strategies evaluated in the LVT DURATION study, a randomized pilot trial sponsored by Queen Mary University of London. The study assesses the optimal duration of anticoagulation in patients with left ventricular thrombus (LVT) who have completed an initial three-month course of therapy, specifically comparing the continuation versus discontinuation of treatment. Rivaroxaban and apixaban are direct oral anticoagulants (DOACs) that act as selective inhibitors of Factor Xa, while warfarin is a vitamin K antagonist that inhibits the synthesis of vitamin K-dependent clotting factors by targeting the vitamin K epoxide reductase complex (VKORC1). These medications are used to prevent systemic thromboembolic complications, such as stroke, in patients with LVT following myocardial infarction or in the setting of cardiomyopathy.

Other names

Direct oral anticoagulantsDOACsVitamin K antagonistsVKA